Evidence map›Paper›PMID 41456320›Full record

ArticleJournal of chemical information and modeling2026

Probing the Structural Dynamics of the Unbound MAX Protein: Insights from Well-Tempered Metadynamics.

Huixia Lu, Jordi Marti, Jordi Faraudo

Abstract read
In one paragraph

Article in Journal of chemical information and modeling, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Whole-Genome Sequencing of Multidrug-ResistantInternational journal of molecular sciences · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Huixia LuInstitut de Ciència de Materials de Barcelona (ICMAB-CSIC), Campus de la UAB, 08193 Bellaterra, Spain.ORCID 0000-0003-2731-5283
Jordi MartiDepartment of Physics, Universitat Politècnica de Catalunya-Barcelona Tech (UPC), 08034 Barcelona, Spain.ORCID 0000-0002-3721-9634
Jordi FaraudoInstitut de Ciència de Materials de Barcelona (ICMAB-CSIC), Campus de la UAB, 08193 Bellaterra, Spain.ORCID 0000-0002-6315-4993

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

One of most relevant challenges in tumorigenesis is the association of MYC and MAX proteins, whose related cancers remain undrugged. In particular, the disordered regions shown by those oncogenes make their structural characterization and the development of new drugs a truly hard task. To address these challenges, we employed the enhanced-sampling well-tempered metadynamics method to systematically explore the conformational space of the unbound MAX protein. Our results revealed, for the first time, a well-defined and thermodynamically favorable conformation of monomeric MAX. This is a remarkable finding, as it demonstrates that regions of MAX previously considered persistently disordered are capable of adopting stable, folded structures under specific conditions. Moreover, our findings also suggest that the metastable structural motifs observed in this work may harbor druggable sites, particularly relevant for strategies aiming to target MAX directly or to disrupt its interaction with MYC, thereby modulating oncogenic signaling pathways. The present study establishes a new structural framework for understanding the dynamics of MAX and provides a foundation for future structure-based drug design targeting the MYC/MAX axis. Finally, our work offers a strategic blueprint for investigating similarly challenging drug targets.

Indexed as

Basic Helix-Loop-Helix Leucine Zipper Transcription FactorsMolecular Dynamics SimulationProtein ConformationThermodynamicsBasic Helix-Loop-Helix Leucine Zipper Transcription Factors

Identifiers

PMID41456320
PMCPMC12801308

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.